These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 32168428)

  • 1. A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
    Yamano T; Kubo S; Tomita N
    Cancer Med; 2020 May; 9(10):3337-3343. PubMed ID: 32168428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
    Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
    Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
    Chen CW; Wang WM; Su YC; Wu JY; Hsieh JS; Wang JY
    Med Princ Pract; 2008; 17(6):496-9. PubMed ID: 18836281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Sugisawa N; Nishino H; Higuchi T; Park JH; Yamamoto J; Tashiro Y; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
    Anticancer Res; 2020 Oct; 40(10):5393-5397. PubMed ID: 32988858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
    Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
    Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
    Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
    Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Folprecht G; Köhne CH; Lutz MP
    Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
    Surinach A; Phung T; Abdul-Rahim O; Khushman M
    Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
    El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539
    [No Abstract]   [Full Text] [Related]  

  • 20. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
    J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.